Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
NCT00003334
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin and paclitaxel in treating patients who have recurrent or refractory endometrial cancer, fallopian tube cancer, or sarcoma of the female reproductive tract.
Gender:
FEMALE
Ages:
120 years and below
Trial Updated:
03/10/2016
Locations: Albert Einstein Comprehensive Cancer Center, Bronx, New York +4 locations
Conditions: Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma
Register for Updates
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
NCT00370552
Completed
The purpose of this clinical research study is to learn if ixabepilone plus bevacizumab is effective in shrinking or stopping the growth of cancer when given as first-line chemotherapy in participants with metastatic breast cancer. The study will also assess the safety of this combination treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2016
Locations: East Valley Hematology And Oncology Medical Group, Burbank, California +24 locations
Conditions: Metastatic Breast Cancer
Register for Updates
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
NCT00533585
Completed
The goal of this study is to find the highest tolerable dose of BAY 43-9006 (sorafenib) and bevacizumab that can be given with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). The safety and effectiveness of this drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2016
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
Hepatic Arterial Infusion (HAI) of Abraxane
NCT00732836
Completed
The goal of this clinical research study is find the highest tolerated dose of Abraxane (nab-paclitaxel) that can be given directly into the liver of patients with advanced cancer that has spread to the liver.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2016
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Liver Cancer, Advanced Cancers, Solid Tumors
Register for Updates
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
NCT00455533
Completed
The study will evaluate the effectiveness of ixabepilone when given after doxorubicin plus cyclophosphamide (AC) compared to standard treatment of paclitaxel given after doxorubicin plus cyclophosphamide in patients with early stage breast cancer. In addition the study will verify predefined biomarkers as well as discover new biomarkers that could identify patients who are more likely to respond to ixabepilone than standard paclitaxel based therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/25/2016
Locations: Comprehensive Cancer Center, Palm Springs, California +49 locations
Conditions: Breast Cancer
Register for Updates
Combination Paclitaxel, Carboplatin and Temozolomide
NCT00249964
Completed
The purpose of this study is to determine the maximum tolerable dose of temozolomide in combination with fixed dose of paclitaxel and carboplatin and to determine the overall tumor response rate with this combination and to determine the duration of response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2016
Locations: University of New Mexico Cancer Center, Albuquerque, New Mexico
Conditions: Lung Diseases, Cancer
Register for Updates
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
NCT00738361
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with metastatic melanoma of the eye that cannot be removed by surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2016
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Intraocular Melanoma
Register for Updates
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
NCT01200342
Terminated
The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2016
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Melanoma
Register for Updates
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
NCT01256762
Completed
The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or metastatic breast cancer who have not received chemotherapy or have received one non-taxane based chemotherapy for metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2015
Locations: Clearview Cancer Center, Huntsville, Alabama +54 locations
Conditions: Locally Recurrent or Metastatic Breast Cancer
Register for Updates
Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility
NCT00617370
Completed
The purpose of this study is to give a drug regimen that is hoped to be effective in preventing cancer from coming back. Since it is an aggressive breast cancer, there is a moderate to high chance that the cancer may come back. The standard treatment for this tumor type includes a chemotherapy regimen with drugs named epirubicin (E) and cyclophosphamide (C) in a vein every 2 weeks for 4 treatments, followed by a drug named paclitaxel, every 2 weeks in your vein for 4 treatments. This study is a... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/21/2015
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Breast Cancer, Adenocarcinoma of the Breast
Register for Updates
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer
NCT01304784
Completed
This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/15/2015
Locations: Rocky Mountain Cancer Centers, Denver, Colorado +14 locations
Conditions: HER-2 Gene Amplification
Register for Updates
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT00588237
Completed
The purpose of this study is to test whether it is safe to treat your cancer with 3 drugs instead of 2 drugs. After surgery, your cancer is typically treated with 2 drugs called cisplatin and paclitaxel (also known as Taxol). Cisplatin is given through a port in your belly, and Taxol is given both through the belly port and through the vein (IV). Large clinical studies have shown that this treatment gives the best results for women with your cancer. This treatment, however, also causes many side... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/15/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Ovarian Cancer, Primary PERITONEUM, Fallopian Tube Cancer
Register for Updates